👶Pregnancy
Human outcome data are limited. Amphetamine exposure in pregnancy may be associated with risks like premature birth and low birth weight, and newborns may have withdrawal-like symptoms (agitation, irritability, excessive drowsiness, feeding difficulties). Nonmedication approaches are preferred for mild to moderate ADHD during pregnancy; for moderate to severe impairment, shared decision-making is key, using the lowest effective dose and the fewest medications possible. Consider enrollment in the National Pregnancy Registry for ADHD Medications (1-866-961-2388).🤱Breastfeeding
Lisdexamfetamine converts to dextroamphetamine, which can be present in breast milk. Reported relative infant doses (RID) across amphetamine/dextroamphetamine sources have ranged roughly 2% to 13.8% of the weight-adjusted maternal dose, and long-term neurodevelopmental outcomes are not well established. The manufacturer recommends avoiding breastfeeding due to potential serious adverse reactions (including cardiovascular effects and growth suppression). If used during breastfeeding in carefully selected cases, use the lowest effective dose and monitor the infant for feeding problems, irritability, insomnia, or excessive sleepiness.👧Children & Adolescents (Under 18)
FDA-approved for ADHD in ages 6+ (not recommended under 6). Typical starting dose is 20 to 30 mg once daily in the morning, with increases by 10 mg/day or 20 mg/day every 3 to 7 days until optimal response; max 70 mg/day. Monitor appetite, weight, height/growth velocity, sleep, mood/behavior, and tics.👴Older Adults (65+)
Use caution. Older adults can be more sensitive to stimulant adverse effects (BP/HR increases, insomnia, anxiety, appetite/weight loss). Start low, titrate slowly, and monitor cardiovascular status closely.🔬Liver Impairment
No manufacturer dose adjustment provided.💧Kidney Impairment
Dose caps apply in moderate to severe renal impairment: max 50 mg/day at GFR 15 to <30; max 30 mg/day at GFR <15 or ESRD on hemodialysis.